

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, Ohara S, Tsukamoto N, Kurose N, Yamada S, Takai K, <b>Aoki S, Masaki Y.</b>	Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan.	International Journal of Hematology	113(1)	73-80	2021
Van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, <b>Ida M,</b> et al.	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castlemans disease	Blood Adv	3(4)	6039-6050	2020
佐々木祥, <b>中山健夫.</b>	GRADEシステムによる診療ガイドライン. Author : 佐々木 祥(京都大学大学院医学研究科社会健康医学系専攻健康情報学分野), 中山 健夫 Source : 腫瘍内科 (1881-6568)26巻3号 Page341-346(2020.09)	腫瘍内科	26(3)	341-346	2020
Shiroshita K, Kikuchi T, Okayama M, Kasahara H, Kamiya T, Shimizu T, Kurose N, <b>Masaki Y,</b> Okamoto S.	Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease.	Intern Med	59(23)	3061-3065	2020
<b>Masaki Y,</b> Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, Kurose N, Miura K, Nakamura S, Aoki S & Japanese TAFRO syndrome research team.	2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome.	Int J Hematol	111(1)	155-158	2020
Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. ; Akamizu T, Akiyama M, Barra L, Bateman A, Blockmans D, Brito-Zeron P, Campochiaro C, Carruthers M, Chiba T, Cornell L, Culver E, Darabian S, Deshpande V, Dong L, Ebbo M, Fernández-Codina A, Ferry JA, Fragkoulis G, Frost F, Frulloni L, Hernandez-Molina G, Ji H, Keat K, Kamisawa T, Kawa S, Kobayashi H, Kodama Y, Kubo S, Kubota K, Leng H, Lerch M, Liu Y, Liu Z, Löhr M, Martin-Nares E, Martinez-Valle F, Marvisi C, <b>Masaki Y,</b> Matsui S, Mizushima I, Nakamura S, Nordeide J, Notohara K, Paire S, Popovic J, Ramos-Casals M, Rosenbaum J, Ryu J, Sato Y,	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.	Ann Rheum Dis	79(1)	77-87	2020

Sekiguchi H, Sokol EV, Stone JR, Sun W, Takahashi H, Takahira M, Tanaka Y, Vaglio A, Villamil A, Wada Y, Webster G, Yamada K, Yamamoto M, Yi J, Yi Y, Zamboni G, Zhang W.					
Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, <b>Masaki Y</b> , Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T.	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.	Lancet Oncol	21(4)	593-602	2020
Miura K, Tsujimura H, <b>Masaki Y</b> , Iino M, Takizawa J, Maeda Y, Yamamoto K, Tamura S, Yoshida A, Yagi H, Yoshida I, Kitazume K, Masunari T, Choi I, Kakinoki Y, Suzuki R, Yoshino T, Nakamura S, Hatta Y, Yoshida T, Kanno M.	Consolidation with Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.	Hematol Oncol	39(1)	51-59	2020
Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, <b>Masaki Y</b> , Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H; Japan Clinical Oncology Group.	A randomized phase II/III study of R-CHOP versus CHOP combined with dose-dense rituximab for DLBCL: JCOG0601.	Blood Adv	5(4)	984-993	2020
Kawakita E, Yang F, Kumagai A, Takagaki Y, Kitada M, Yoshitomi Y, Ikeda T, Nakamura Y, <b>Ishigaki Y</b> , Kanasaki K, Koya D.	Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling.	Mol Cancer Res	19(1)	61-73	2020
Mizunuma Y, Kanasaki K, Nitta K, Nakamura Y, <b>Ishigaki Y</b> , Takagaki Y, Kitada M, Li S, Liu H, Li J, Usui I, Aso Y, Koya D.	CD-1db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis.	J Diabetes Investig	11(6)	1470-1481	2020
Ishida H, Shibata T, Nakamura Y, <b>Ishigaki Y</b> , Singh P.D, Sasaki H, Kubo E.	Identification of Differential Gene Expression Pattern in Lens Epithelial Cells Derived from Cataractous and Noncataractous Lenses of Shumiya Cataract Rat.	Biomed Res Int	2	7319590	2020
He Q, Sawada M, Yamasaki N, Akazawa S, Furuta H, Uenishi H, Meng X, Nakahashi T, Ishigaki Y, Moriya J.	Neuroinflammation, Oxidative Stress, and Neurogenesis in a Mouse Model of Chronic Fatigue Syndrome, and the Treatment with Kampo Medicine.	Biol Pharm Bull	43(1)	110-115	2020

Zheng J, Guo X, Nakamura Y, Zhou X, Yamaguchi R, Zhang J, <b>Ishigaki Y</b> , Uramoto H, Yamada S.	Overexpression of PRDX4 Modulates Tumor Microenvironment and Promotes Urethane-Induced Lung Tumorigenesis.	Oxid Med Cell Longev	28	8262730	2020
Inoue S, Takata T, Nakazawa Y, Nakamura Y, Guo X, Yamada S, <b>Ishigaki Y</b> , Takeuchi M, Miyazawa K.	Potential of an Interorgan Network Mediated by Toxic Advanced Glycation End-Products in a Rat Model.	Nutrients	13(1)	80	2020
Mizuno H, <b>Sawa N</b> , Watanabe S, Ikuma D, Sekine A, Kawada M, Yamanouchi M, Hasegawa E, Suwabe T, Hoshino J, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Nagata M, Yamaguchi Y, Ubara Y.	The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome.	Kidney Int Rep	5(8)	1172-1179	2020
Nishimura MF, Igawa T, Gion Y, Tomita S, Inoue D, Izumozaki A, Ubara Y, Nishimura Y, Yoshino T, <b>Sato Y</b> .	Pulmonary manifestations of plasma cell type idiopathic multicentric Castleman disease: a clinicopathological study in comparison with IgG4-related disease.	J Pers Med	10	269	2020
Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, <b>Sato Y</b> , Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F.	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.	Am J Hematol.	95(12)	1553-1561	2020
Yu L, Shi M, Cai QQ, Strati P, Hagemester F, Zhai QL, Li L, Fan X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, Iwaki N, <b>Sato Y</b> , Zhang L, Li J, Oksenhendler E, Xu-Monette ZY, Young KH.	A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.	Oncologist	25(11)	963-973	2020
Kawano M, Hara S, Yachie A, <b>Sato Y</b> , Fajgenbaum DC.	HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease.	Reumatology (Oxford)	60(1)	e3-e4	2021
Han Y, Igawa T, Ogino K, Nishikori A, Gion Y, Yoshino T, <b>Sato Y</b> .	Hemosiderin deposition in lymph nodes of patients with plasma cell-type Castleman disease.	J Clin Exp Hematop	60(1)	1-6	2020

書籍

なし